TESTER CONSTRUCTION GIVES INC

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2022

Legal Domicile

Principal Officer

MICHAEL TESTER

Tax Period

2024-01-01 to 2024-12-31

TESTER CONSTRUCTION GIVES INC, founded in 2022, is a micro nonprofit in the Medical Research sector that reported $38K in total revenue in fiscal year 2024. Revenue fell 86% from the prior year — a significant decline worth monitoring. Expenses of $43K exceeded revenue, resulting in a 11% operating deficit.

Mission

TCGIVES WAS BORN IN MEMORY OF KATHLEEN K. SCHOEMAKER WHO LOST HER BATTLE TO PANCREATIC CANCER IN 2006. TCGIVES WILL RAISE MONEY TO PROMOTE PROGRESS IN THE DIAGNOSIS AND TREATMENT OF PANCREATIC CANCER IN HONOR OF KATHLEEN. EVERY YEAR, MORE THAN 66,440 AMERICANS ARE DIAGNOSED WITH PANCREATIC CANCER, THE THIRD-LEADING CAUSE OF CANCER DEATH IN THE COUNTRY. THROUGH FUNDRAISING EFFORTS TCGIVES, IN PARTNERSHIP WITH JEFFERSON'S SIDNEY KIMMEL CANCER CENTER, WANT TO GIVE THE GIFT OF HOPE TO PATIENTS AND FAMILIES MET WITH A DIAGNOSIS OF PANCREATIC CANCER.

Program Service Accomplishments

Program 1

Expenses: $39,725

WE ARE, AND CONTINUE TO BE, OVERWHELMED BY DR. YEO'S TEAMS DEDICATION TO THEIR PATIENTS, THEIR FOCUS ON IMPROVING THEIR PATIENTS QUALITY OF LIFE, AND THEIR COMMITMENT TO FINDING A CURE TO PANCREATIC CANCER. TCG GIVES HAS PARTNERED WITH DR. YEO'S TEAM AND JEFFERSON'S SIDNEY KIMMEL CANCER CENTER THAT WE MAY ADVANCE TREATMENT OPTIONS FOR THOSE DIAGNOSED WITH PANCREATIC CANCER. THIS INITIATIVE SEEKS TO IDENTIFY BIOMARKERS IN EARLY STAGE TUMORS, WHICH CAN IN TURN INFORM TUMOR-SPECIFIC TREATMENT AND POTENTIALLY PREDICT DRUG RESPONSE AND DISEASE RECURRENCE. BIOMARKER TESTING IS NOT COVERED UNDER INSURANCE AND RELIES COMPLETELY ON DONATIONS FROM ORGANIZATIONS LIKE TCG GIVES. THIS RESEARCH WILL ADVANCE PANCREATIC CANCER TREATMENT AND IMPROVE SURVIVAL RATES, ULTIMATELY PROVIDING THE BIGGEST GIFT TO THOSE FACED WITH PANCREATIC CANCER: HOPE. JEFFERSON HAS THE TOP PANCREATIC SURGICAL AND RESEARCH TEAM IN THE COUNTRY, LED BY DR. CHARLES YEO. TCG GIVES PROCEEDS WILL GO DIRECTLY TO DR. YEO'S MOLECULAR PROFILING INITIATIVE. ONE OF THE GOALS OF JEFFERSONS' RESEARCH IS TO PROFILE EACH PATIENT'S TUMOR. AS DESCRIBED BY DR. YEO. "BY PROFILING EACH PATIENT'S TUMOR, WE CAN BETTER TARGET THEIR SPECIFIC CANCER. THIS IS THE DIRECTION OF MODERN, PERSONALIZED ONCOLOGIC CARE, NOT TO MENTION ADVANCES OUR RESEARCH". THERE IS LIMITED FUNDING FROM NIH AND THE AMERICAN CANCER SOCIETY AND THEREFOR JEFFERSON'S RESEARCH TEAM RELIES ON PHILANTHROPY TO CONTINUE TO CREATE FORWARD MOVEMENT IN TREATING THIS DISEASE.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $38,464

Program Service Revenue $0

Investment Income $0

Other Revenue $0

TOTAL REVENUE $38,464

Expense Breakdown

Grants Paid $7,500

Salaries & Benefits $0

Fundraising Expenses $80

Program Expenses $39,725

Other Expenses $35,292

TOTAL EXPENSES $42,792

Year-over-Year Comparison

	2024	2023	Change
Revenue	$38,464	$283,624	-0.9%
Expenses	$42,792	$285,787	-0.9%
Net Income	$-4,328	$-2,163	+1.0%

Key Indicators

✓ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

N/A

Employees

N/A

Volunteers

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

⚠ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
MICHAEL TESTER	PRESIDENT	1.50	Officer Director	$0	$0	$0
KRISTEN TESTER	SECRETARY	1.50	Officer Director	$0	$0	$0
MARISSA TESTER	TREASURER	1.50	Officer Director	$0	$0	$0
ANNEMARIE TESTER	BOARD MEMBER	1.50	Director	$0	$0	$0
WILLIAM TESTER	BOARD MEMBER	1.50	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	No data	No data	No data	No data
2024	$38,464	$42,792	$2,006	$-4,328
2023	$283,624	$285,787	$6,334	$-2,163
2022	$233,107	$224,610	$8,497	$8,497